169 related articles for article (PubMed ID: 20208555)
1. Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5.
Walter K; Cockerill PN; Barlow R; Clarke D; Hoogenkamp M; Follows GA; Richards SJ; Cullen MJ; Bonifer C; Tagoh H
Oncogene; 2010 May; 29(20):2927-37. PubMed ID: 20208555
[TBL] [Abstract][Full Text] [Related]
2. Lineage-inappropriate PAX5 expression in t(8;21) acute myeloid leukemia requires signaling-mediated abrogation of polycomb repression.
Ray D; Kwon SY; Tagoh H; Heidenreich O; Ptasinska A; Bonifer C
Blood; 2013 Aug; 122(5):759-69. PubMed ID: 23616623
[TBL] [Abstract][Full Text] [Related]
3. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.
Tiacci E; Pileri S; Orleth A; Pacini R; Tabarrini A; Frenguelli F; Liso A; Diverio D; Lo-Coco F; Falini B
Cancer Res; 2004 Oct; 64(20):7399-404. PubMed ID: 15492262
[TBL] [Abstract][Full Text] [Related]
4. Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22).
Valbuena JR; Medeiros LJ; Rassidakis GZ; Hao S; Wu CD; Chen L; Lin P
Am J Clin Pathol; 2006 Aug; 126(2):235-40. PubMed ID: 16891199
[TBL] [Abstract][Full Text] [Related]
5. B-cell transcription factor expression and immunoglobulin gene rearrangement frequency in acute myeloid leukemia with t(8;21)(q22;q22).
Johnson RC; Ma L; Cherry AM; Arber DA; George TI
Am J Clin Pathol; 2013 Sep; 140(3):355-62. PubMed ID: 23955454
[TBL] [Abstract][Full Text] [Related]
6. Stem cell-specific epigenetic priming and B cell-specific transcriptional activation at the mouse Cd19 locus.
Walter K; Bonifer C; Tagoh H
Blood; 2008 Sep; 112(5):1673-82. PubMed ID: 18552207
[TBL] [Abstract][Full Text] [Related]
7. [Expression of the transcription factor PAX5 in childhood acute leukemic cells].
Zhang B; Tie LJ; Ye QD; Gu LJ; Tang JY; Yuan XL; Shen LS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):6-10. PubMed ID: 16584581
[TBL] [Abstract][Full Text] [Related]
8. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
[TBL] [Abstract][Full Text] [Related]
9. Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19.
Plesa A; Labussière-Wallet H; Hayette S; Salles G; Thomas X; Sujobert P
Haematologica; 2019 Oct; 104(10):e487-e488. PubMed ID: 31197067
[No Abstract] [Full Text] [Related]
10. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
Bousquet M; Broccardo C; Quelen C; Meggetto F; Kuhlein E; Delsol G; Dastugue N; Brousset P
Blood; 2007 Apr; 109(8):3417-23. PubMed ID: 17179230
[TBL] [Abstract][Full Text] [Related]
11. In vivo footprinting and mutational analysis of the proximal CD19 promoter reveal important roles for an SP1/Egr-1 binding site and a novel site termed the PyG box.
Riva A; Wilson GL; Kehrl JH
J Immunol; 1997 Aug; 159(3):1284-92. PubMed ID: 9233624
[TBL] [Abstract][Full Text] [Related]
12. [The Immunophenotypical features of t (8; 21) (q22; q22) acute myeloid leukemia].
Pan X; Li J; Xia X; Geng M; Wang A; Zhu M; Chen L; Guo Y; Xue Y
Zhonghua Xue Ye Xue Za Zhi; 2001 Jun; 22(6):313-5. PubMed ID: 11877092
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of sense and antisense promoter activity at the Csf1R locus in B cells by the transcription factor PAX5.
Ingram RM; Valeaux S; Wilson N; Bouhlel MA; Clarke D; Krüger I; Kulu D; Suske G; Philipsen S; Tagoh H; Bonifer C
Exp Hematol; 2011 Jul; 39(7):730-40.e1-2. PubMed ID: 21549805
[TBL] [Abstract][Full Text] [Related]
14. Combined heterozygous loss of Ebf1 and Pax5 allows for T-lineage conversion of B cell progenitors.
Ungerbäck J; Åhsberg J; Strid T; Somasundaram R; Sigvardsson M
J Exp Med; 2015 Jun; 212(7):1109-23. PubMed ID: 26056231
[TBL] [Abstract][Full Text] [Related]
15. Role of CD19 and specific KIT-D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities.
Wang B; Yang B; Ling Y; Zhang J; Hua X; Gu W; Yan F
Cancer Med; 2021 Feb; 10(3):1091-1102. PubMed ID: 33382538
[TBL] [Abstract][Full Text] [Related]
16. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34.
Kita K; Nakase K; Miwa H; Masuya M; Nishii K; Morita N; Takakura N; Otsuji A; Shirakawa S; Ueda T
Blood; 1992 Jul; 80(2):470-7. PubMed ID: 1378322
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus.
Souabni A; Jochum W; Busslinger M
Blood; 2007 Jan; 109(1):281-9. PubMed ID: 16968900
[TBL] [Abstract][Full Text] [Related]
18. Stepwise activation of enhancer and promoter regions of the B cell commitment gene Pax5 in early lymphopoiesis.
Decker T; Pasca di Magliano M; McManus S; Sun Q; Bonifer C; Tagoh H; Busslinger M
Immunity; 2009 Apr; 30(4):508-20. PubMed ID: 19345119
[TBL] [Abstract][Full Text] [Related]
19. Acute myelogenous leukemia with t(8;21)--identification of a specific immunophenotype.
Khoury H; Dalal BI; Nevill TJ; Horsman DE; Barnett MJ; Shepherd JD; Toze CL; Conneally EA; Sutherland HJ; Hogge DE; Nantel SH
Leuk Lymphoma; 2003 Oct; 44(10):1713-8. PubMed ID: 14692523
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of tumor suppressors in t(8:21)-containing AML.
Yang G; Khalaf W; van de Locht L; Jansen JH; van der Reijden BA; Müller-Tidow C; Delwel HR; Serve H; Clapp DW; Hiebert SW
Ann Hematol; 2004; 83 Suppl 1():S83. PubMed ID: 15124686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
